These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3860480)

  • 1. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data.
    De Leonardis V; Neri B; Bacalli S; Cinelli P
    Int J Clin Pharmacol Res; 1985; 5(2):137-42. PubMed ID: 3860480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens.
    De Leonardis V; De Scalzi M; Neri B; Bartalucci S; Cinelli P
    Int J Clin Pharmacol Res; 1987; 7(4):307-11. PubMed ID: 3474215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
    Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
    J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
    Neri B; Cini-Neri G; Bandinelli M; Pacini P; Bartalucci S; Ciapini A
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):217-21. PubMed ID: 2737789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection.
    Mortensen SA; Aabo K; Jonsson T; Baandrup U
    Int J Clin Pharmacol Res; 1986; 6(2):137-50. PubMed ID: 3459718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angelica sinensis: a novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity.
    Xin YF; Zhou GL; Shen M; Chen YX; Liu SP; Chen GC; Chen H; You ZQ; Xuan YX
    Basic Clin Pharmacol Toxicol; 2007 Dec; 101(6):421-6. PubMed ID: 17971065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
    Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
    Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?
    Köseoğlu V; Berberoğlu S; Karademir S; Kismet E; Yurttutan N; Demirkaya E; Sungur M; Alehan D
    Turk J Pediatr; 2005; 47(1):17-22. PubMed ID: 15884624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
    Saad SY; Najjar TA; Alashari M
    J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
    Li W; Xu B; Xu J; Wu XL
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrocardiographic and biochemical evidence for the cardioprotective effect of vitamin E in doxorubicin-induced acute cardiotoxicity in rats.
    Puri A; Maulik SK; Ray R; Bhatnagar V
    Eur J Pediatr Surg; 2005 Dec; 15(6):387-91. PubMed ID: 16418954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography.
    Elbl L; Hrstkova H; Chaloupka V; Novotny J; Michalek J
    Neoplasma; 2003; 50(3):191-7. PubMed ID: 12937852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiotoxicity of anthracyclines].
    Ferrière M; Donadio D; Ramirez R
    Arch Mal Coeur Vaiss; 1993 Feb; 86 Spec No 2():53-8. PubMed ID: 8215791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of left ventricular function in patients with mammary carcinoma after treatment with epidoxorubicin using a high-dose, short-term protocol].
    D'Alto M; Maurea S; Basso A; Polverino W; Bianchi U; Bonelli A; Silvestro P; Salvatore M; Chiariello M
    Cardiologia; 1997 Jun; 42(6):611-8. PubMed ID: 9289377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of doxorubicin cardiotoxicity by carnitine is specific of the L-diasteroisomer.
    Maccari F; Ramacci MT
    Biomedicine; 1981 May; 35(2):65-7. PubMed ID: 7260239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography.
    Gillings S; Johnson J; Fulmer A; Hauck M
    Vet Ther; 2009; 10(1-2):46-58. PubMed ID: 19742448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
    Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
    Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.